J
Jinming Yu
Researcher at Peking Union Medical College
Publications - 517
Citations - 9367
Jinming Yu is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 40, co-authored 419 publications receiving 6476 citations. Previous affiliations of Jinming Yu include Xinjiang Medical University & Zhengzhou University.
Papers
More filters
Journal ArticleDOI
PD-L1 expression in human cancers and its association with clinical outcomes
TL;DR: Better understanding of tumor microenvironment and use of other biomarkers such as gene marker and combined index are necessary to better identify patients who will benefit from PD-1/PD-L1 checkpoint blockade therapy.
Journal ArticleDOI
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
Yang Liu,Yang Liu,Yinping Dong,Yinping Dong,Li Kong,Fang Shi,Hui Zhu,Hui Zhu,Jinming Yu,Jinming Yu +9 more
TL;DR: The most significant purpose of this review is to identify the potential predictors of the abscopal effect to help identify the most appropriate patients who would most likely benefit from the combination treatment modality.
Journal ArticleDOI
A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.
Shuanghu Yuan,Xindong Sun,Minghuan Li,Jinming Yu,Rui-Mei Ren,Yonghu Yu,Jianbin Li,Xiuqing Liu,Renben Wang,Baosheng Li,Li Kong,Yong Yin +11 more
TL;DR: Outcome improvement can be expected by conformal IFI combined with chemotherapy for stage III NSCLC by achieving better overall response and local control than ENI arm, and it allowed a dose of 68 to 74 Gy to be safely administered to patients with inoperable stage IIINSCLC.
Journal ArticleDOI
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
TL;DR: The combination of a PD-1/PD-L1 checkpoint blockade with RT, TMZ, antibodies targeting other inhibitory or stimulatory molecules, targeted therapy, and vaccines may be an appealing solution aimed at achieving optimal clinical benefit in glioblastoma.
Journal ArticleDOI
Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
TL;DR: The current progress and challenges of developing predictive biomarkers of immunotherapy responsiveness are discussed, aiming to provide some directions for future studies.